Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 60 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Parkinson's Disease, Essential Tremor, Dystonia
Interventions: Dexmedetomidine Hydrochloride Infusion, Normal Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Idiopathic Scoliosis, Spondylolisthesis
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Julia Finkel; Other
Eligibility: 10 Years to 18 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes Mellitus, Type 2
Interventions: L-Lysine, Normal Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Genital Herpes Simplex Type 2
Interventions: Matrix-M2, GEN-003, Placebo; Biological · Drug
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Ebola Hemorrhagic Fever
Interventions: AVI-7537, Normal Saline Solution (NSS); Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: AG-920; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Meningococcal Disease
Interventions: MenABCWY, Placebo, MenACWY; Biological · Other
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: Alemtuzumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Weeks to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Wounds and Injuries, Multiple Trauma, Disorder of Fluid Balance
Interventions: Plasmalyte A, Normal Saline; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Epistaxis
Interventions: Tranexamic Acid, 0.9% Sodium Chloride; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Muscle Spasticity
Interventions: botulinum toxin Type A, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Downey, California • Daytona Beach, Florida

Conditions: COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions: Sodium Nitrite, Normal Saline; Drug
Lead sponsor: Hope Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Tampa, Florida • Fort Worth, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: AVI-4658 (Eteplirsen), Placebo; Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 7 Years to 13 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Septic Shock
Interventions: L-Carnitine, Normal Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Jackson, Mississippi • Charlotte, North Carolina

Conditions: Knee Osteoarthritis
Interventions: Platelet Rich Plasma, Normal Saline; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 40 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Benign Prostatic Hyperplasia
Interventions: botulinum toxin Type A, Normal saline; Drug
Lead sponsor: Allergan; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Cervical Spine Fusion
Interventions: Bupivacaine Hcl 0.25% Inj, Normal saline; Drug · Other
Lead sponsor: Hartford Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Renal Transplantation, Mesenchymal Stem Cells
Interventions: Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion; Biological · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Paracervical Block
Interventions: Lidocaine paracervical block, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Postoperative Pain, Paracervical Block, Laparoscopic Gynecologic Surgery
Interventions: Bupivacaine, Normal Saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Bronchiolitis
Interventions: 3% sodium chloride, 0.9% sodium chloride; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 12 Months
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Bacterial Reduction on Skin Flora Post-product Application
Interventions: ChloraPrep Hi-Lite Orange, Normal saline, 3M CHG/IPA Prep Tint 10.5-mL, 3M CHG/IPA Prep Tint 26-mL; Drug
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sterling, Virginia

Search by objective public record fields.

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia

Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Precision Dosing of Alemtuzumab

Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

L-Carnitine Administration in Early Sepsis

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

Paracervical Block During Office Hysteroscopy

Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis

In-vivo Efficacy Study of Patient Pre-operative Preps